Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)

Inclusion Criteria: * Newly diagnosed symptomatic multiple myeloma (MM) patient * Aged under 65 * Candidate for ASCT, with measurable levels of paraprotein in the serum (³ 10 g/L) or the urine (³ 200 mg/day) * Using effective contraceptive methods (for fertile men, women of childbearing potential) * Provision of informed consent * No evidence of active infection Exclusion Criteria: * Asymptomatic MM * Non-secretory MM * Aged 66 years or over * ECOG performance status over 2 (see Appendix 2) * Proven amyloidosis * A personal medical history of cancer (except for basocellular skin cancer or in situ cervical cancer) * Positive HIV serology * A personal medical history of severe psychiatric disease * Severe diabetes contraindicating the use of high-dose dexamethasone * NCI grade ³ 2 peripheral neuropathy * Serum clinical chemistry: * creatinine level \> 300 µmol/L or requiring dialysis * bilirubin, transaminases or GamaGT \> 3 the upper normal limit (UNL) * Prior or current systemic therapy for MM, including steroids (except for emergency use of a 4-day block of dexamethasone between the screening phase and randomization) * Radiation therapy in the 2 weeks preceding randomization * A personal medical history of allergic reactions to compounds containing boron or mannitol * Non-controlled or severe cardiovascular disease (including a myocardial infarction in the 6 months prior to recruitment) or NYHA class III or IV renal failure * Use of any investigational drug in the 30 days preceding randomization * Pregnant or lactating women; a serum Beta-hCG pregnancy test must be performed during the screening phase for female patients of childbearing potential * Severe pulmonary troubles (including acute infiltrative pneumopathy)